In treatment naïve RR-MS patients (CARE-MS I trial), 8.0% (95% CI 5.7 – 11.2) of MS patients in the alemtuzumab group showed 24-week (CDW) at year 2, being the difference not significant compared with the IFN arm (11.1%, 95% CI 7.3 – 16.7, p=0.22); accordingly, changes in EDSS score from baseline did not differ between the alemtuzumab and IFN groups (p=0.97) (94). This evidence concerns the gene IFNA1 and myeloid sarcoma.